Skip to main content
Equibles
INTI logo

INTI · Inhibitor Therapeutics, Inc.

Track INTI — free

Use INTI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INTI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.11 At close · Oct 16
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions and events raise substantial doubt about the Company's ability to continue as a going concern. ... Because management's plans have not yet been fully executed and are not within the Company's control, the implementation of such plans cannot be considered probable. As a result, the Company has concluded that management's plans do not currently alleviate substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$19.12M
Shares
173.79M
Volume · Oct 16 3900 Avg daily vol (3M) 15.6K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.11 Open$0.07 Day$0.06–0.11 52W close$0.04–0.12 Avg vol 30d15K Short int5K · 0.0% float · 1.0d Short vol52% DataJan 2020–Oct 2026 Filing10-Q · Aug 14

Up next

Latest filing: 10-Q
filed Aug 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$3.31M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$467,930
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.4%
Year over year · more shares
Price change (1Y)
+129.0%
Trailing year
Short interest
—
Latest settlement
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +69%
above
Price vs 50-day avg +33%
above
RSI (14) 57
neutral
MACD trend Positive
52-week position 83%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +86%
trailing
6-month return +120%
trailing
YTD return +144%
this year
Relative strength +113%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Fundamentals
Strong
EPS growth 0%
Y/Y
Balance sheet $2.3M
net cash
Quant / Vol
risk profile
Very High
Volatility 257%
annualized · 1-yr
Max drawdown −53%
past year
ATR 19.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+69% Bullish
Price vs 50-day avg
+33% Bullish
RSI (14)
57 Neutral
MACD trend
Positive Bullish
52-week position
83% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross) No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0 Now $0 · 83% Range high $0
vs 200-day avg +69% vs 50-day avg +33%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
INTI
Inhibitor Therapeutics, Inc.
this stock
$19.12M +144.2% — — 0.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +13.5% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +4.6% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $64.50B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest
Shares short
4.6K
Days to cover
1.0d
Change
0 sh
View
Short Volume
Short vol %
52%
As of
Oct 16, 2026
Short Total
View
Fails to Deliver
FTD shares
490
Value
$44
As of
Mar 10, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-3.3M
EPS diluted
$-0.02
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 18, 2026
This year
9
View
Earnings & Events
Webcasts
Last webcast
Sep 15, 2026
View

Performance

5D 20D 120D MTD YTD
INTI +9.9% +86.3% +119.8% +9.9% +144.2%
SPY -2.0% +0.2% +6.7% +0.1% +11.9%
vs SPY +11.9% +86.1% +113.1% +9.8% +132.3%
Key facts CIK 1042418 CUSIP 45720M105 Visit website Investor relations